ClinicalTrials.gg
CompletedNCT05495243Updated Jul 23, 2025

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

A Phase 2 interventional study of ARINA-1 and Placebo in Non-cystic Fibrosis Bronchiectasis, sponsored by Renovion, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Renovion, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Enrollment
36th of 52
40 · median 78
Started
2022
with 2 others
Phase 2
15 of 65
4 open now
Registered
41st of 65
by date

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 36th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2022, is one of 15 in phase 2, and was the 41st registered.

Bronchiectasis

405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety and efficacy of ARINA-1 compared to placebo (isotonic saline, 0.9%) in participants with NCFBE. Study participants will receive either study treatment or placebo twice daily for 28 days. Efficacy endpoints will include quality of life, sputum rheological markers, and blood inflammatory markers. Quality of life will be measured using the following tools: Quality of Life-Bronchiectasis (QOL-B) questionnaire, St. George's Respiratory Questionnaire (SGRQ), Chronic Airways Assessment Test (CAAT), and a daily clinical global impression questionnaire.

03

Conditions studied

  • Non-cystic Fibrosis Bronchiectasis

Browse trials for

Keywords

  • bronchiectasis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of NCFBE confirmed by chest CT
  • 18-80 years old, inclusive at time of
  • >18
  • Percent predicted > 40%, pre-bronchodilator
  • Stable for 90 days with any airway clearance technique (ACT) method(s)
  • Stable on standard of care (SOC) therapy for 90 days (includes cycling antibiotics, such as inhaled tobramycin, and long-term macrolide therapy) and not likely, in the opinion of the investigator, to require any changes to therapy during the duration of study participation
  • Fully vaccinated for COVID-19 (second dose of a 2-shot regimen or single dose of 1-shot regimen completed >14 days prior to the screening visit)
  • Must be able to produce a sputum sample
  • If female and of , must be willing to use for the duration of the study.

Exclusion criteria

Exclusion Criteria

  • Positive urine pregnancy test for women of (WOCBP) at screening and baseline visit
  • Active exacerbation ≤28 days prior to the baseline visit
  • Initiating or changing antibiotic, antiviral, or antifungal therapy ≤ 28 days prior to the baseline visit
  • Changing or initiating any vitamin C, glutathione or N-acetyl-cysteine-containing therapy or multivitamin within 30 says prior to the screening visit.
  • Positive COVID-19 diagnostic test (PCR or antigen) within 90 days prior to the screening visit.
  • Participated in other interventional drug or device studies within 30 days of the screening visit (Note: observational studies are acceptable)
  • Significant unstable comorbidities (in the opinion of the site investigator), such as heart failure, cardiovascular disease, diabetes, renal disease, liver disease
  • Current tobacco or marijuana smoker (those with active smoking exposure \<180 days prior to the screening visit) (Note: edibles are acceptable)
  • Requiring the use of any supplemental oxygen
  • Currently on cycled antibiotics (e.g., tobramycin) or have been on a cycled antibiotic regimen within 90 days prior to the screening visit.
  • Current diagnosis of non-tuberculous mycobacteria (NTM) requiring antibiotic treatment. (Participants who test positive for NTM but who are not currently on antibiotic therapy are eligible for screening)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ARINA-1

    ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH); fixed dose, 4 mL solution inhaled twice daily via nebulization for 28 days

    Drug: ARINA-1

  • Placebo comparator
    Placebo

    Isotonic saline (0.9%); 4 mL solution inhaled twice daily via nebulization for 28 days

    Drug: Placebo

Interventions

  • DrugARINA-1

    ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)

  • DrugPlacebo

    Isotonic saline (0.9%)

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Incidence of participants that experience an adverse event following administration of treatment

    Time frame: 56 days

  2. Proportion of participants that experience each treatment-emergent adverse event

    Time frame: 56 days

Secondary outcomes

  1. Compare quality of life (as measured by CAAT questionnaire) between the ARINA-1 and placebo arms

    8 questions rated on a 0-5 scale

    Time frame: 56 days

  2. Compare quality of life (as measured by SGRQ) between the ARINA-1 and placebo arms

    42 questions, ranked on a 5-point descriptive scale or true/false

    Time frame: 56 days

  3. Compare quality of life (as measured by QOL-B) between the ARINA-1 and placebo arms

    37 questions ranked on a 4-point descriptive scale

    Time frame: 56 days

  4. Compare blood inflammatory markers between the ARINA-1 and placebo arms

    C-reactive protein

    Time frame: 56 days

  5. Compare changes in mucolytic use between ARINA-1 and placebo arms

    Compare the initiation or changes to regimen for drugs such as n-acetylcysteine, dornase alfa, etc. This information will be collected at all clinic visits and phone calls.

    Time frame: 56 days

  6. Compare changes in airway clearance techniques between ARINA-1 and placebo arms

    Compare the initiation or changes to regimen for airway clearance techniques such as chest physical therapy, high-frequency oscillating vest therapy, etc. This information will be collected at all clinic visits and phone calls.

    Time frame: 56 days

  7. Compare FEV1 between the ARINA-1 and treatment arms

    measured in L

    Time frame: 56 days

  8. Compare FVC between the ARINA-1 and treatment arms

    measured in L

    Time frame: 56 days

  9. Compare FEF25-75 between the ARINA-1 and treatment arms

    measured in L/sec

    Time frame: 56 days

  10. Compare PEF between the ARINA-1 and treatment arms

    measured in L/min

    Time frame: 56 days

  11. Compare sputum percent solids between the ARINA-1 and placebo arms

    Time frame: 56 days

07

Study locations

10 sites
  • University of Alabama - Birmingham
    Birmingham, Alabama 35294, United States
  • National Jewish Hospital
    Denver, Colorado 80206, United States
  • Georgetown University
    Washington D.C., District of Columbia 20007, United States
  • Louisiana State University
    New Orleans, Louisiana 70803, United States
  • Johns Hopkins
    Baltimore, Maryland 21205, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Jefferson Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas - Tyler
    Tyler, Texas 29425, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Feb 2024, 15 months.

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Aug 10, 2022
StartActual
Oct 3, 2022
Primary completionActual
Feb 1, 2024
CompletionActual
Feb 1, 2024
Results delay requested
Jan 23, 2025
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05495243
Lead sponsor
Renovion, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2022
Start date
Oct 3, 2022
Primary completion
Feb 1, 2024
Completion
Feb 1, 2024
Last update
Jul 23, 2025

Study contacts

Charles L Daley, MD
principal investigator · National Jewish Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion